CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
Curis, Inc.
Curis, Inc.
Incyte Corporation
Dren Bio
AVM Biotechnology Inc
Lyell Immunopharma, Inc.
Nurix Therapeutics, Inc.
Nurix Therapeutics, Inc.
Merck Sharp & Dohme LLC
Genmab
Arovella Therapeutics Ltd
Bristol-Myers Squibb
SecuraBio
Artiva Biotherapeutics, Inc.
AstraZeneca
Hoffmann-La Roche
Hoffmann-La Roche
AvenCell Therapeutics, Inc.
Acerta Pharma BV
Vironexis Biotherapeutics Inc.
Pfizer
VIVUS LLC
Treeline Biosciences, Inc.
ADC Therapeutics S.A.
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Taiho Oncology, Inc.
Nurix Therapeutics, Inc.
Fate Therapeutics
Cellectar Biosciences, Inc.
Cellectar Biosciences, Inc.
Merck Sharp & Dohme LLC
Sellas Life Sciences Group
Electra Therapeutics Inc.
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
Innovent Biologics (Suzhou) Co. Ltd.
Allogene Therapeutics
BeOne Medicines
Lyell Immunopharma, Inc.
ModeX Therapeutics, An OPKO Health Company
Allogene Therapeutics
Allogene Therapeutics
Takeda
Gamida Cell ltd
Otsuka Pharmaceutical Co., Ltd.
Ossium Health, Inc.
Takeda
Hutchmed
Spectrum Pharmaceuticals, Inc
Hoffmann-La Roche
Celgene
GeoVax, Inc.